Twist Bioscience Corp (0ME.SG)
| Previous close | 26.90 |
| Open | 26.63 |
| Bid | 26.72 x 280000 |
| Ask | 27.03 x 190000 |
| Day's range | 26.53 - 26.63 |
| 52-week range | 10.37 - 38.64 |
| Volume | |
| Avg. volume | 20 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireTwist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss i
Simply Wall St.Despite shrinking by US$135m in the past week, Twist Bioscience (NASDAQ:TWST) shareholders are still up 132% over 1 year
Twist Bioscience Corporation ( NASDAQ:TWST ) shareholders might be concerned after seeing the share price drop 13% in...
Business WireTwist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
SOUTH SAN FRANCISCO, Calif., March 28, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES).
